Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1614 1616 1628
This examiner grants 42% of resolved cases
Jean P. Cornet is an examiner in Tech Center 1600 and Art Unit 1614. He has reached a final disposition in 1186 resolved cases. The allowance rate for these cases is 42.1%. The median days to allowance is 1116 days. This 1116-day period provides a specific timeline for the duration of the examination process in his portfolio.
The interview lift for this examiner is 47.5%. This metric indicates that conducting an interview is associated with an increase in the probability of an allowance compared to cases without such engagement. With 1186 resolved cases, the 42.1% allowance rate represents the frequency of grants in his portfolio. Practitioners in Tech Center 1600 can use the 47.5% lift to assess the impact of direct communication. The 1116-day median pendency is a factor for managing expectations in Art Unit 1614.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18720572 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18006584 | USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND FOR PREVENTING, ALLEVIATION, OR TREATING MASTOCYTOSIS | Final Rejection | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18008750 | REJUVENATION OF AGED TISSUES BY INHIBITION OF THE PGE2 DEGRADING ENZYME, 15-PGDH | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17355727 | COMPOSITIONS AND METHODS FOR INDUCING APPENDAGE AND LIMB REGENERATION | Final Rejection | California Institute of Technology |
| 18835261 | USE OF RETINOIDS FOR TREATMENT OF ATRIAL FIBRILLATION | Non-Final OA | NEW YORK UNIVERSITY |
| 18678355 | SOLID FORMS | Non-Final OA | Gilead Sciences, Inc. |
| 18376308 | DISINFECTING COMPOSITION, APPLICATOR, AND METHOD OF DISINFECTING | Final Rejection | Medline Industries, LP |
| 17231273 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | Battelle Memorial Institute |
| 18021643 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | Non-Final OA | BIOGEN MA INC. |
| 18631595 | Glutamate receptor agonists for suppression of mast cell function | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17440895 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | Final Rejection | Cornell University |
| 18697835 | INHIBITORS OF ULK1 AND METHODS OF USE | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18257680 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 17495069 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | Non-Final OA | CAAMTECH, INC. |
| 18714760 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | Non-Final OA | Celgene Corporation |
| 17639993 | USE OF 5-METHYLTETRAHYDROFOLATE | Final Rejection | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. |
| 17798131 | PHARMACEUTICAL COMPOSITION FOR INHIBITING INFLAMMATORY RESPONSE COMPRISING HYDROXYUREA | Non-Final OA | BIONOXX INC. |
| 18267591 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | Non-Final OA | ZEVRA DENMARK A/S |
| 17612950 | OXATHIAZIN COMPOUNDS FOR INHIBITING GAPDH | Non-Final OA | Geistlich Pharma AG |
| 17310971 | MODULATORS OF TDP-43 | Final Rejection | Alteron Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy